Updates are available Correction dated 2021-11-01
Click to view Correction: https://doi.org/10.1186/s12931-021-01874-x
-
Authors
Núñez, Alexa
Belmonte, Irene
Miranda, Elena
Barrecheguren, Miriam
Farago, Georgina
Loeb, Eduardo
Pons, Mònica
Rodríguez-Frías, Francisco
Gabriel-Medina, Pablo
Rodríguez, Esther
Genescà, Joan
Miravitlles, Marc http://orcid.org/0000-0002-9850-9520
Esquinas, Cristina
-
Funding
Funding for this research was provided by:
grifols
- License Information
-
More Information
Article History
Received: 2 July 2021
Accepted: 8 September 2021
First Online: 15 September 2021
Change Date: 1 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-021-01874-x
Declarations
:
: The study was carried out according to the principles of the Declaration of Helsinki and the prevailing norms for performing investigation in humans. Data confidentiality was ensured according to the Law of Data Protection 2016/679. The study was approved by the Ethical Committee and Clinical Investigation of the Vall d’Hebron University Hospital (Barcelona, Spain) number PR (AG) 156/2016, and all the participants provided written informed consent.
: Not applicable.
: Cristina Esquinas has received speaker fees from CSL Behring. Marc Miravitlles has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Laboratorios Esteve, Gebro Pharma, Kamada, GlaxoSmithKline, Grifols, Johson & Johnson, Menarini, Mereo Biopharma, Novartis, pH Pharma, Palobiofarma SL, Rovi, TEVA, Spin Therapeutics, Verona Pharma and Zambon, and research grants from Grifols. Miriam Barrecheguren has received speaker fees from Grifols, Menarini, CSL Behring, GSK and consulting fees from GSK, Novartis, Boehringer Ingelheim and Gebro Pharma. Esther Rodríguez has received speaker fees from CSL Behring, TEVA and GlaxoSmithKline. The remaining authors report no conflicts of interest.
